Farnesyl pyrophosphate synthase


  • Accession: P14324
  • Swissprot: FPPS_HUMAN
  • Organism: Homo sapiens
  • Gene: FDPS
  • Target class: Enzyme

Drug Relations:

alendronic acid
A nonhormonal medication for the treatment of postmenopausal osteoporosis in women. This drug builds healthy bone, restoring some of the bone loss as a result of osteoporosis. Bioactivity details MOA
ibandronic acid
Bioactivity details MOA
incadronic acid
increases serum 1,25-dihydroxyvitamin D in rats via stimulating renal 1-hydroxylase activity; structure given in first source Bioactivity details MOA
pamidronic acid
inhibits osteolytic bone lesions; inhibits the mevalonate pathway, which is required for the prenylation of the small GTPase; RN given refers to parent cpd Bioactivity details MOA
risedronic acid
An aminobisphosphonate derivative of etidronic acid and CALCIUM CHANNEL BLOCKER that inhibits BONE RESORPTION and is used for the treatment of OSTEOPOROSIS. Bioactivity details MOA
zoledronic acid
a potent inhibitor of bone resorption; structure given in first source Bioactivity details MOA
minodronic acid
Bioactivity details MOA
neridronic acid
used for therapy of Paget's disease of bone & malignant hypercalcaemia Bioactivity details MOA
sodium pyrophosphate
Bioactivity details MOA